N4 PHARMA PLC

Regulatory Filings • Feb 6, 2025

National Storage Mechanism | Additional information

RNS Number : 0537W

Ananda Pharma PLC

06 February 2025

06 February 202 5

ANANDA PHARMA PLC  

("Ananda" or the "Company")  

Appointment of Commercial Adviser

Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as a commercial adviser. Mr Rust will provide the Company with expert advice on its drug development and commercialisation plans.

Highlights:

·    Mr Rust is a highly experienced pharmaceutical executive with direct experience marketing and selling licensed drugs in the US and in the pain sector

·    Mr Rust has served as a senior commercial executive of several international pharmaceutical companies over a 30-year career

Mr Rust's most recent role was as Global Head of Respiratory with Chiesi Group, an international biopharmaceutical company which has a direct presence in 31 countries. At Chiesi, Mr Rust l ed the strategic direction and execution of the group's respiratory portfolio, which included products for asthma and COPD, to significantly grow revenues for the company's respiratory range to in excess of €1.5 billion.

Ananda's CEO, Melissa Sturgess commented : "We are delighted to have Andy join us as a commercial adviser. In our determination to bring cannabinoid drugs to market, including two forthcoming NHS sponsored phase 3 clinical trials, we are ensuring we always have our focus on the prize, which means understanding the marketing and sales ramifications of all our decisions along the way."  

About Ananda Pharma

Ananda Pharma (AQSE: ANA), is a UK-based developer of licenced, CBD-based medicinal products.  Ananda is developing a range of cannabinoid-based medicines targeting the treatment of complex, chronic inflammatory pain conditions. The Company is led by successful entrepreneurs and a team of world-class scientists.

For more information, please visit: www.anandapharma.co.uk

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn :   https://www.linkedin.com/company/anandapharma

·              X : https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-  

The Directors of the Company accept responsibility for the contents of this announcement.  

ANANDA PHARMA PLC	+44 (0)7463 686 497
	ir@anandapharma.co.uk
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	+44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	+44 (0)20 3004 9512 ananda@yellowjerseypr.com

https://investors.anandapharma.co.uk/link/MrDQpP

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATAMJTMTMMBLA